Launch timetable is now imminent for developers of a revolutionary system for medication management as they open an initial SAFE investment round and will fund final product development and market validation in compelling use-case.
Read MoreNew preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called the body's natural "cell cycle brake." These results build on prior STAT1 data, supporting Telomir-1's profile as a potential first-in-class broad-spectrum DNA methylation reset therapy.
Read More
- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -
- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -
Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time
Read More- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody
- Safety profile observed in first four dose cohorts supports continued development
- No serious adverse events or dose-limiting toxicities have been reported
Read More
· Research focused on long-acting therapeutics based on Remedium's proprietary Prometheus™ platform
· Multiple targets for the treatment of Obesity and Type 2 Diabetes
Read More
Is the DEA the Epitome of Ineptitude?
"Why is the VA importing cannabis that U.S. companies have been ready to produce for years? If American cannabis is ‘too dangerous' for research, why is foreign cannabis treatment suddenly acceptable for our veterans?" asked Duane Boise, CEO of MMJ International Holdings.
Read More
Pace® expert to leverage extensive knowledge to provide guidance on risk assessments for pharmaceutical and biopharmaceutical companies
Read More
Finetech, a top manufacturer of pharmaceutical machinery, announces its new technology for the NJP 1200 capsule filling machine. This machine can fuse soft capsule + granule into one hard capsule.
Read MoreCurrent FX rates indicate that the LTM August 2025 Revenue would be approximately $58M with $6M in EBITDA
Sportstech announced May to August 2025 revenue growth of 20% YOY
TRNR Investment in Sportstech working capital is accelerating growth for the pending acquisition, with full-year 2025 Revenue growth expected to exceed 30%
Strong Business Momentum and Profitable Growth Reinforces Underscore Target's Operational Strength and Logic of Acquisition in advance of Closing
Read MoreNew candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells
Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins Aptevo's introduction of new, trispecific CD3-directed anti-cancer molecules
Read More
New Data Describe Lab-Grown Amebocytes (aLAL™) That Aim to Match Native LAL Performance While Solving Supply, Cost and Sustainability Constraints
Read More
Virtue Recovery has expanded its Business Development Team with the addition of two American Veterans, Adam Khosroabadi and Chauncy Nash. Both bring extensive military service, professional expertise, and a passion for helping others, strengthening Virtue Recovery's mission to provide compassionate, whole-person treatment across its nationally accredited centers.
Read More
